The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K pathway is frequently activated in bladder urothelial cancers.
• Targeting this pathway presents a potential therapeutic strategy for bladder cancer.

Purpose of the Study:

• To evaluate the therapeutic potential of PI3K pathway inhibitors in bladder cancer.
• To elucidate the mechanisms of action and resistance to PI3K inhibitors.
• To identify predictive biomarkers for treatment response.

Main Methods:

• Analysis of bladder cancer cell lines and patient-derived xenografts (PDXs) for PI3K pathway alterations.
• Sensitivity testing of pictilisib alone and in combination with cisplatin and/or gemcitabine.
• RNA sequencing to investigate drug resistance mechanisms.

Main Results:

• Pictilisib demonstrated sensitivity in cell lines and PDX models with specific PIK3CA mutations or amplification.
• Pictilisib showed synergistic effects with cisplatin and gemcitabine, delaying tumor growth and prolonging survival.
• Phosphorylation of ribosomal protein S6 correlated with response, suggesting it as a predictive biomarker.
• Activation of the MEK/ERK pathway and LSP1 downregulation were identified as resistance mechanisms.

Conclusions:

• Preclinical data support the therapeutic potential of targeting the PI3K pathway in bladder cancer.
• Combination therapy with pictilisib and chemotherapy warrants further investigation.
• Understanding resistance mechanisms can guide the development of more effective treatment strategies.